Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.53 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 5/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9494162 | 0.98 | KCNH2 (0.64) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| Hydrochloric Acid SCHEMBL6206412 | 0.98 | KCNH2 (0.60) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| SCHEMBL9493891 | 0.98 | KCNH2 (0.64) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| SCHEMBL31549854 | 0.98 | KCNH2 (0.64) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| SCHEMBL6216002 | 0.98 | KCNH2 (0.64) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| SCHEMBL9492760 | 0.98 | KCNH2 (0.64) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| SCHEMBL31549845 | 0.98 | KCNH2 (0.64) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| SCHEMBL31549853 | 0.98 | KCNH2 (0.64) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| SCHEMBL6944812 | 0.94 | KCNH2 (0.55) | KCNH2GNAI3GNAO1GNAI1S1PR5 | |
| Sulfuric Acid SCHEMBL9493803 | 0.92 | KCNH2 (0.58) | KCNH2GNAI3GNAO1GNAI1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-A1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| CN-102356065-B | Piperidine derivatives as NK3 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-01 | — | — | CN | disclosed |
| WO-2014142363-A1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-18 | — | — | WO | disclosed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8314113-B2 | Substituted dihydroquinazolines II | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| EP-2408745-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2010106081-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-23 | — | — | WO | disclosed |
| US-20070281953-A1 | Substituted Dihydroquinazolines II | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | US | disclosed |
| EP-1768959-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006004793-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-12 | — | — | WO | disclosed |
| EP-0300462-B1 | HETEROCYCLIC PEROXYCARBOXYLIC ACIDS | AUSIMONT S.p.A. (IT) | 1993-09-29 | — | — | EP | disclosed |
| US-5071584-A | Storage stable, heat resistant | AUSIMONT S.P.A. (IT) | 1991-12-10 | — | — | US | disclosed |
| EP-0300462-A2 | Heterocyclic peroxycarboxylic acids | AUSIMONT S.p.A. (IT) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | KCNH2 104/4885GNAI3 521/4885GNAO1 788/4885 |
| US-20070281953-A1 | Substituted Dihydroquinazolines II | EIF2AK2, QDPR, IRF3 | KCNH2 3979/4885GNAI3 179/4885GNAO1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.